JW Lifescience Balance Sheet Health
Financial Health criteria checks 6/6
JW Lifescience has a total shareholder equity of ₩159.4B and total debt of ₩46.2B, which brings its debt-to-equity ratio to 29%. Its total assets and total liabilities are ₩255.8B and ₩96.4B respectively. JW Lifescience's EBIT is ₩30.9B making its interest coverage ratio 19.7. It has cash and short-term investments of ₩28.3B.
Key information
29.0%
Debt to equity ratio
₩46.22b
Debt
| Interest coverage ratio | 19.7x |
| Cash | ₩28.35b |
| Equity | ₩159.39b |
| Total liabilities | ₩96.44b |
| Total assets | ₩255.84b |
Recent financial health updates
We Think JW Lifescience (KRX:234080) Can Manage Its Debt With Ease
Apr 20
We Think JW Lifescience (KRX:234080) Can Manage Its Debt With Ease
Jan 12
Recent updates
We Think JW Lifescience (KRX:234080) Can Manage Its Debt With Ease
Apr 20Introducing JW Lifescience (KRX:234080), A Stock That Climbed 36% In The Last Year
Mar 11What Type Of Shareholders Make Up JW Lifescience Corporation's (KRX:234080) Share Registry?
Feb 21Is JW Lifescience Corporation (KRX:234080) A Smart Pick For Income Investors?
Feb 02We Think JW Lifescience (KRX:234080) Can Manage Its Debt With Ease
Jan 12Is It Smart To Buy JW Lifescience Corporation (KRX:234080) Before It Goes Ex-Dividend?
Dec 23Is JW Lifescience Corporation's (KRX:234080) Recent Performance Tethered To Its Attractive Financial Prospects?
Dec 23How Much Did JW Lifescience's(KRX:234080) Shareholders Earn From Share Price Movements Over The Last Three Years?
Nov 27Financial Position Analysis
Short Term Liabilities: A234080's short term assets (₩107.8B) exceed its short term liabilities (₩94.3B).
Long Term Liabilities: A234080's short term assets (₩107.8B) exceed its long term liabilities (₩2.2B).
Debt to Equity History and Analysis
Debt Level: A234080's net debt to equity ratio (11.2%) is considered satisfactory.
Reducing Debt: A234080's debt to equity ratio has reduced from 50.4% to 29% over the past 5 years.
Debt Coverage: A234080's debt is well covered by operating cash flow (81.3%).
Interest Coverage: A234080's interest payments on its debt are well covered by EBIT (19.7x coverage).